126 related articles for article (PubMed ID: 25294870)
21. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial.
Kang EH; Lee IS; Chung SK; Lee SY; Kim EJ; Hong JP; Oh KS; Woo JM; Kim S; Park JE; Yu BH
Psychiatry Res; 2009 Sep; 169(2):118-23. PubMed ID: 19695711
[TBL] [Abstract][Full Text] [Related]
22. Association of the TLR4 gene with depressive symptoms and antidepressant efficacy in major depressive disorder.
Wang J; Yang C; Liu Z; Li X; Liu M; Wang Y; Zhang K; Sun N
Neurosci Lett; 2020 Sep; 736():135292. PubMed ID: 32763359
[TBL] [Abstract][Full Text] [Related]
23. Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients.
Laakmann G; Hennig J; Baghai T; Schüle C
Ann N Y Acad Sci; 2004 Dec; 1032():279-82. PubMed ID: 15677428
[TBL] [Abstract][Full Text] [Related]
24. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
McGrath PJ; Stewart JW; Fava M; Trivedi MH; Wisniewski SR; Nierenberg AA; Thase ME; Davis L; Biggs MM; Shores-Wilson K; Luther JF; Niederehe G; Warden D; Rush AJ
Am J Psychiatry; 2006 Sep; 163(9):1531-41; quiz 1666. PubMed ID: 16946177
[TBL] [Abstract][Full Text] [Related]
25. Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population.
Yang Z; Ma X; Wang Y; Wang J; Xiang B; Wu J; Deng W; Li M; Wang Q; Li T
Gen Hosp Psychiatry; 2012; 34(5):571-7. PubMed ID: 22795047
[TBL] [Abstract][Full Text] [Related]
26. Low-dose mirtazapine in treatment of major depression developed following severe nausea and vomiting during pregnancy: two cases.
Uguz F
Gen Hosp Psychiatry; 2014; 36(1):125.e5-6. PubMed ID: 24034854
[TBL] [Abstract][Full Text] [Related]
27. Real-world, open-label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder.
Wang D; Li Z; Li L; Hao W
Asia Pac Psychiatry; 2014 Jun; 6(2):152-60. PubMed ID: 23857869
[TBL] [Abstract][Full Text] [Related]
28. Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression.
Gupta R; Gupta K; Tripathi AK; Bhatia MS; Gupta LK
Pharmacology; 2016; 97(3-4):184-8. PubMed ID: 26854819
[TBL] [Abstract][Full Text] [Related]
29. The effects of mirtazapine on sleep in patients with major depressive disorder.
Dolder CR; Nelson MH; Iler CA
Ann Clin Psychiatry; 2012 Aug; 24(3):215-24. PubMed ID: 22860241
[TBL] [Abstract][Full Text] [Related]
30. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study.
Haapasalo-Pesu KM; Vuola T; Lahelma L; Marttunen M
J Child Adolesc Psychopharmacol; 2004; 14(2):175-84. PubMed ID: 15319015
[TBL] [Abstract][Full Text] [Related]
31. Influence of mirtazapine on urinary free cortisol excretion in depressed patients.
Schule C; Baghai T; Rackwitz C; Laakmann G
Psychiatry Res; 2003 Oct; 120(3):257-64. PubMed ID: 14561437
[TBL] [Abstract][Full Text] [Related]
32. Mirtazapine for treatment-resistant depression: a preliminary report.
Wan DD; Kundhur D; Solomons K; Yatham LN; Lam RW
J Psychiatry Neurosci; 2003 Jan; 28(1):55-9. PubMed ID: 12587851
[TBL] [Abstract][Full Text] [Related]
33. Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment.
Liou YJ; Chen TJ; Tsai SJ; Yu YW; Cheng CY; Hong CJ
Pharmacogenet Genomics; 2009 Oct; 19(10):735-41. PubMed ID: 19741570
[TBL] [Abstract][Full Text] [Related]
34. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients.
Shen J; Moller HJ; Wang X; Chung SA; Shapiro GK; Li X; Shapiro CM
J Clin Psychiatry; 2009 Mar; 70(3):370-7. PubMed ID: 19192466
[TBL] [Abstract][Full Text] [Related]
35. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study.
Schosser A; Calati R; Serretti A; Massat I; Kocabas NA; Papageorgiou K; Linotte S; Mendlewicz J; Souery D; Zohar J; Juven-Wetzler A; Montgomery S; Kasper S
Eur Neuropsychopharmacol; 2012 Apr; 22(4):259-66. PubMed ID: 21940152
[TBL] [Abstract][Full Text] [Related]
36. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
Tsai SJ; Hong CJ; Liou YJ; Chen TJ; Chen ML; Hou SJ; Yen FC; Yu YW
Psychiatry Res; 2009 Sep; 169(2):113-7. PubMed ID: 19700204
[TBL] [Abstract][Full Text] [Related]
37. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
38. Depressed in-patients respond differently to imipramine and mirtazapine.
Bruijn JA; Moleman P; Mulder PG; van den Broek WW
Pharmacopsychiatry; 1999 May; 32(3):87-92. PubMed ID: 10463374
[TBL] [Abstract][Full Text] [Related]
39. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.
Okumura T; Kishi T; Okochi T; Ikeda M; Kitajima T; Yamanouchi Y; Kinoshita Y; Kawashima K; Tsunoka T; Inada T; Ozaki N; Iwata N
Neuropsychobiology; 2010; 61(2):57-63. PubMed ID: 20016223
[TBL] [Abstract][Full Text] [Related]
40. Tobacco use is associated with low peripheral beta-arrestin 1 levels in major depression: A preliminary report.
Mesdom P; Colle R; Becquemont L; Chappell K; David DJ; Mendez-David I; Corruble E; Verstuyft C
Drug Alcohol Depend; 2022 Nov; 240():109653. PubMed ID: 36209675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
